eprex pfs 4000 iu/0.4ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - epoetin alfa 4000 iu/0.4ml - 4000 iu/0.4ml
eprex pfs 10000 iu/ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - erythropoietin alfa 10000 iu/ml - 10000 iu/ml
eprex pfs 2000 iu/0.5ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - erythropoietin alfa 2000 iu/0.5ml - 2000 iu/0.5ml
eprex pfs 40000 iu
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - epoetin alfa 40000 iu - 40000 iu
eprex 40,000 iu/ml solution for injection in pre-filled syringe
janssen-cilag ltd - epoetinum alfa - solution for injection - 40, 000 international unit(s)/millilitre - other antianemic preparations; erythropoietin
eprex 2,000 iu/ml solution for injection in pre-filled syringe
janssen-cilag ltd - epoetin alfa - solution for injection in pre-filled syringe - 2000 international unit(s)/millilitre - other antianemic preparations; erythropoietin
eprex 4,000 iu/ml solution for injection in pre-filled syringe
janssen-cilag ltd - epoetin alfa - solution for injection - 4000 unit(s)/millilitre - other antianemic preparations; erythropoietin
eprex 10,000 iu/ml solution for injection in pre-filled syringe
janssen-cilag ltd - epoetin alfa - solution for injection in pre-filled syringe - 10000 international unit(s)/millilitre - other antianemic preparations; erythropoietin
recormon 2000 iu
roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
recormon 3000 iu
roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative